Biotech Values

[DewDiligence]

OPGN reverse-merges into CURE.AS:

https://www.globenewswire.com/news-release/2019/09/04/1910618/0/en/Curetis-and-OpGen-Enter-Into-Definitive-Agreement-to-Combine-Businesses.html

At the closing of the transaction, Curetis N.V. will be entitled to receive 2,662,564 new shares of common stock of OpGen (less the number of shares to be reserved for issuance to current holders of options, phantom stock and convertible debt securities issued by Curetis N.V.), reflecting a valuation of the combined business of roughly $24 million.

As of September 3, 2019, these 2,662,564 new shares would represent approximately 72.5% of the outstanding equity of OpGen (on a fully diluted basis), and current equity holders of OpGen (including option holders and warrant holders) would hold approximately 27.5% of the equity of OpGen (on a fully diluted basis). The respective equity holdings upon Closing will be subject to any dilutive issuance of securities by OpGen between the date hereof and the date of Closing.

OPGN is +80% and CURE.AS is +21% on this news.